Chinese Expert Consensus on Prevention and Treatment of Hyperkalemia Related to Heart Failure Medication Therapy
10.3969/j.issn.1000-3614.2024.06.002
- VernacularTitle:心力衰竭药物治疗相关高钾血症防治专家共识
- Author:
Cardiovascular Medicine Branch of Chinese Physicians Association
;
Electrophysiology and Cardiac Function Branch of Chinese Society of Geriatrics
;
Jingmin ZHOU
;
Jiefu YANG
- Keywords:
heart failure;
renin-angiotensin system inhibitor;
mineralocorticoid receptor antagonist;
medication therapy;
hyperkalemia;
consensus
- From:
Chinese Circulation Journal
2024;39(6):537-546
- CountryChina
- Language:Chinese
-
Abstract:
Renin-angiotensin system inhibitors,angiotensin receptor neprilysin inhibitors,and mineralocorticoid receptor antagonists are the cornerstone medications for the treatment of heart failure,but they are also major causes of hyperkalemia.Patients with heart failure who develop hyperkalemia have an increased risk of mortality and rehospitalization.Reducing or discontinuing these drugs are associated with higher risk of adverse outcome than hyperkalemia itself.To reduce hyperkalemia risk in patients with heart failure and standardize the management,experts from Cardiovascular Medicine Branch of Chinese Physicians Association and Electrophysiology and Cardiac Function Branch of Chinese Society of Geriatrics developed this consensus,referring to the latest domestic and international guidelines/consensus opinions on hyperkalemia management and clinical research results,and considering the national situation and clinical practice in China.The consensus mainly includes the epidemiology of hyperkalemia in heart failure patients,standardized the use of heart failure treatment drugs,identification,monitoring,follow-up,and prevention of heart failure patient at high risk of hyperkalemia,as well as application strategies of potassium-lowering medication,aiming to provide clinicians with guidance for early prevention and treatment on heart failure medication-related hyperkalemia.
